Medical Products Agency

What Medical Products Agency does

The Medical Products Agency (Läkemedelsverket) is Sweden's national regulatory authority for pharmaceuticals, medical devices, and clinical trials, established in 1993 and headquartered in Uppsala. It is a government state entity operating under the Ministry of Health and Social Affairs, with 501-1,000 employees, and holds statutory responsibility for scientific evaluation, marketing authorization, and post-market surveillance of medicines and medical products within the Swedish market while operating within the broader EU regulatory framework.

The agency's core technology and operational platform is its regulatory review and approval system, encompassing clinical trial application assessment, marketing authorization decisions, adverse event monitoring, and product quality investigation. Its work covers both traditional pharmaceuticals and advanced therapy categories, evidenced by recent activity including the August 2025 conditional approval of Lifileucel (Amtagvi) tumor-infiltrating lymphocyte therapy and joint authorization of a Phase 1/2a SYN321 knee osteoarthritis study enrolling 35 participants. The agency also coordinates with the Swedish Ethical Review Authority on trial oversight and engages in cross-border post-market surveillance, as demonstrated by its 2025 coordination on contaminated wet wipes linked to 6 deaths and 59 infections in the UK.

As a government authority, the Medical Products Agency does not operate a commercial revenue model; it is funded through the state budget rather than product or service pricing. Its "customers" in a regulatory sense are pharmaceutical companies, clinical research organizations, and the Swedish healthcare and public health system, all of which it serves through official regulatory communications, guidance documents, and public health advisories rather than commercial marketing channels. Its strategic position is reinforced by core partnerships with FDA, EMA, Health Canada, UK MHRA, the Swedish Ethical Review Authority, and ICH, including recent co-issuance of joint AI practice principles in drug development with EMA and FDA.

Name

Medical Products Agency

Legal name

Läkemedelsverket

Website

https://lakemedelsverket.se

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

501–1,000 employees

Short description

The Medical Products Agency (Läkemedelsverket) is Sweden's national regulatory authority, headquartered in Uppsala, responsible for approving and supervising pharmaceuticals, medical devices, and clinical trials, and coordinating with EMA, FDA, and other international regulators.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulatory Services

NAICS

Administration of Public Health Programs (923120)

SIC

Services-Health Services (8000)

akta.pro primary industry

Drug Regulators (Human Pharmaceuticals) (HLAJADAA)

akta.pro secondary industries

Medical Device Regulators (HLAJADAC), Clinical Trials Authorization & Oversight (GCP) (HLAJADAF)

Keywords

• Pharmaceutical regulation
• Medical device oversight
• Clinical trial approval
• Drug safety surveillance
• Market authorization

Headquarters

HQ city

Uppsala

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Distribution channels1 record

Marketing channels2 records

Core offering

Medical Products Agency (Läkemedelsverket) is the Swedish national authority responsible for the regulation and surveillance of pharmaceutical products, medical devices, and cosmetics. It evaluates and approves marketing authorizations, oversees clinical trials, and conducts post-market surveillance to ensure drug and device safety and efficacy.

Product overview

Medical Products Agency (Läkemedelsverket) is Sweden's national regulatory authority for medicines and medical products. As a government agency, it does not develop or sell commercial products; rather, it oversees regulatory approval, oversight, and market surveillance of pharmaceutical products and medical devices within Sweden.

Differentiator

Problem solved

Functional benefit

Products and services

• Marketing Authorization Review and Approval Regulatory review and approval service for pharmaceutical products and medical devices seeking market authorization in Sweden. For pharmaceutical companies, biotech firms, and medical device manufacturers.
• Clinical Trial Authorization Authorization service for clinical trials of pharmaceutical products conducted in Sweden. For clinical trial sponsors, CROs, and academic researchers.
• Post-Market Pharmacovigilance and Drug Safety Surveillance Ongoing surveillance and safety monitoring of approved pharmaceutical products and medical devices on the Swedish market. For marketing authorization holders and healthcare providers.
• National E-Services Regulatory Platform Digital platform enabling electronic submission and processing of regulatory applications for pharmaceutical products, medical devices, and clinical trials in Sweden.

Quantifiable outcome

• Conditional approval granted August 2025 for Lifileucel within Health Canada framework
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core.

• FDA (U.S. Food and Drug Administration)coreOthersInternational regulatory collaboration on advanced therapies including tumor-infiltrating lymphocyte therapies. FDA approved Lifileucel (Amtagvi) in February 2024; regulatory alignment on approval standards for novel cell therapies.
• Health CanadacoreOthersInternational regulatory partner granting conditional approval for Lifileucel in August 2025, coordinating on advanced melanoma therapy regulatory pathways.
• UK MHRA (Medicines and Healthcare products Regulatory Agency)coreOthersUK regulatory partner currently conducting review and NICE funding appraisal for tumor-infiltrating lymphocyte therapy; collaboration on advanced therapy approval pathways.
• EMA (European Medicines Agency)coreOthersEU regulatory authority with ongoing applications for advanced therapies. EU pharmaceutical legislation agreement published December 2025; joint EMA/FDA principles for good AI practice in drug development issued January 2026.
• Swedish Ethical Review AuthoritycoreOthersNational ethics oversight body collaborating with Swedish Medical Products Agency on clinical trial authorizations. Joint approval of SYN321 phase 1/2a study in August 2025.
• ICH (International Council for Harmonisation)coreOthersInternational harmonization body approving guidelines for real-world evidence, clinical protocols, and safety reporting standards at November 2025 Singapore meeting.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Regional players

• Norwegian Medicines Agency (Statens legemiddelverk): Norway's national medicines regulator, structurally and functionally analogous to Läkemedelsverket, with joint Nordic collaboration on market authorization and pharmacovigilance.
• Finnish Medicines Agency (Fimea): Finland's national medicines and medical devices regulator. Comparable Nordic peer operating under the same EU regulatory framework, with shared responsibilities in clinical trial oversight and pharmacovigilance.
• Danish Medicines Agency (Lægemiddelstyrelsen): Denmark's national medicines regulator, a fellow Nordic authority with closely overlapping responsibilities and frequent bilateral coordination with Läkemedelsverket on Nordic regulatory matters.

Direct peers

• Paul-Ehrlich-Institut (PEI): German federal institute for vaccines and biomedicines, responsible for marketing authorization and safety of biological medicinal products. Comparable to Läkemedelsverket in function and EU member-state scope, with stronger specialization in biologics.
• Agence nationale de sécurité du médicament (ANSM): France's national medicines and medical devices safety agency. Comparable in mandate (drug and device approval, surveillance, clinical trial oversight) and in operating as an EU member-state national competent authority.
• Health Canada: Canada's federal health regulator responsible for drug and medical device approvals. Directly comparable national authority with similar lifecycle regulatory responsibilities, and named as a partner on the Lifileucel conditional approval.
• Therapeutic Goods Administration (TGA, Australia): Australia's national regulator for medicines, medical devices, and biologicals. Comparable in scope and regulatory approach to Läkemedelsverket, and a frequent international partner on mutual recognition and GMP inspections.
• Medicines and Healthcare products Regulatory Agency (MHRA): The UK national regulator for medicines, medical devices, and blood components for transfusion. Directly comparable to Läkemedelsverket as a national medicines regulator, with similar mandate over approvals, clinical trials, and post-market surveillance.

Broad incumbents

• European Medicines Agency (EMA): The central EU regulatory authority for human and veterinary medicines, headquartered in Amsterdam. EMA is the supranational counterpart whose decisions increasingly supersede national agencies like Läkemedelsverket for novel therapies.
• U.S. Food and Drug Administration (FDA): The U.S. federal regulator for drugs, biologics, medical devices, and food. Functionally comparable to Läkemedelsverket but vastly larger in scope, headcount, and global influence, particularly on advanced therapies such as the Lifileucel approval referenced in the data.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/lv_mpa
• Facebookfacebook.com/lakemedelsverket
• LinkedInlinkedin.com/company/swedish-medical-products-agency-lakemedelsverket

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medical Products Agency